BBC News
BBCTrump's nominees for top health jobs agree that Americans need to lose weight, but they disagree on whether they should provide drugs such as Ozempic and Wegovy to achieve that aim - especially when those medicines are quite so expensive.
As a weight management doctor, Mollie Cecil has seen first-hand how the latest weight-loss drugs help her patients.
She knows from personal experience, too. After a year on one medication, the West Virginia doctor lost 40 pounds. Her cholesterol and arthritis improved, allowing her to be more active with her young children.
"I just felt like a new person on them," she said.
But she worried about the same obstacle facing many of her patients - losing insurance coverage - so she tapered off the drugs as a precaution.
It turned out she was right. Dr Cecil later learned her new non-profit insurance plan could not afford to cover the cost of the drugs.
She gradually gained back most of the weight she lost.
A new weight-loss drug policy?
The latest class of weight-loss drugs - also known as GLP-1 agonists - are "the most potent weight-loss medications we have ever had", Dr Cecil said.
"But when I can't get them to [my patients], as a physician who really cares about taking care of people … it just feels helpless," she said.
The new class of drugs - often not covered by private insurance - can cost $1,000 (£809) a month on average. Federal law bans Medicare from covering the drugs when used for weight loss, though they usually are covered when used to treat diabetes and cardiovascular disease. Only 13 states provide coverage under Medicaid for weight loss purposes.
To make them more accessible, then-President Joe Biden recently proposed that Medicare and Medicaid cover them, but now that will be up to President Donald Trump's new administration.
Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's choice to lead Medicare and Medicaid services. But this could mean a potential clash: Kennedy is a vocal critic of the weight-loss drugs while Oz is an ardent advocate.
The Trump administration did not respond to a request for comment about how it would handle the Biden administration's proposal for Medicare - federal insurance for those 65 and older - and Medicaid - government insurance for low-income people - to cover the drugs.
Trump's future approach remains unclear, with several people in his inner circle holding contradictory views, said Jonathan Zhang, a professor at Duke University's Sanford School of Public Policy.
"GLP-1, Ozempic, this is a drug that has so much patient demand," Mr Zhang said. "It's really taken on a life of its own on social media. So the Trump administration - or any administration - faces a tonne of pressure to do something about this in the near term."